RAAS the company has been adhering to the quality policy
RAAS was founded in 1988 and listed on the Shenzhen Stock Exchange in 2008 (stock code: 002252), is a leading blood products company in Asia. Since its establishment 28 years ago, the company has been adhering to the quality policy of "safety, quality and efficiency", and has developed 11 products covering three categories of blood products: human blood protein, human immunoglobulin and coagulation factors, including human albumin, human immunoglobulin, static human immunoglobulin, hepatitis B human immunoglobulin, tetanus toxoid, and human immunoglobulin. Human immunoglobulin, rabies human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin, human fibrinogen, topical lyophilized human fibrin binder. Shanghai RAAS has been registered in nearly 20 countries, and is one of the few domestic manufacturers that can export blood products. Up to now, Shanghai RAAS has 33 plasma stations in China including those under construction, with an annual production capacity of 900 tons of plasma and more than 25 million vials of blood products.
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
ResearchTechnology, Healthcare, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchTechnology, Consumer Staples, Real Estate
Tech for Global, Globalization Footprints of the Established and the New